The present study determined the effect of -angiotensin 1I on steroidogenesis and induced aldosterone synthesis by tihe octapeptide angiotensin 11, the heptapeptide des-Aspl-angiotensin II, and adrenocorticotropic hormone. Rabbit adrenal cells were suspended by incubation of the capsular cortical tissue with collagenase, and aldosterone levels were determined by immunoassay. Steroidogenic responses to angiotensin II and des-Aspl-angiotensin were essentially the same. [Sarl-Ile8J-angiotensin 11 (10-7 to 5 X 10-7 M1) had no significant effect on basal aldosterone biosynthesis. However, when added with steroidogenic peptides, it completely blocked the effect of angiotensin IT and des-Aspl-angiotensin II but not of adrenocorticotropic hormone. The dose ratio of the antagonist to angiotensin II that gave 100% inhibition was about 2:1 and to des-Aspl-angiotensin II, about 50:1.
The data suggest that des-Aspl-angiotensin 11 has a much higher affinity for the angiotensin receptor in adrenal cortex than angiotensin IT.
The renin-angiotensin system plays an important role in the regulation of aldosterone biosynthesis. Brief infusions with the octapeptide anigiotensin II and with renin have been shown to be potent stimuli for aldosterone secretion (1, 2) . Blair-West et al. (3) recently reported that the heptapeptide (des-Aspl-angioten-sin II), a metabolite of angiotensin II, stimulated aldosterone secretion in sheep. In adrenal cortical cell suspensions from cat and dog, this heptapeptide was reported to be more potent than angiotensin II in stimulating the synthesis of aldosterone from ['H]cholesterol (4, 5) . It buffer were added to the cells. The same volume of the drug solvent was added to control samples. In studies with [SarlIle8]-angiotensin II as an antagonist, this compound was added 2 min before the addition of the steroidogenic peptides. The cell suspensions were incubated for 90 additional min, which was experimentally determined to be the total linear period for induced steroidogenesis. Duplicate samples were run in each experiment. dpm of ['H]aldosterone (specific activity 54 Ci/mmol) was added to each sample as an internal standard, immediately followed by the addition of 2 ml of 99% acetone and centrifugation. The supernatant was decanted and retained while the pellet was resuspended in 80% acetone and centrifuged; the supernatant was decanted. The two supernatants were pooled and evaporated to aqueous phase under a stream of N2 at 400. Aldosterone was purified and estimated according to the method of Farmer et al. (9) . The y-lactone radioimmunoassay of Farmer was validated by comparison with the double-isotope derivative method (10) . Results obtained by both methods were essentially identical. Student's t-test was used for statistical evaluation of data. ACTH-induced aldosterone biosynthesis was not affected by [Sarl-Ile8]-angiotensin II in any combination of the concentrations of these two peptides studied. There was no inhibition of des-Aspl-angiotensin 11-induced steroidogenesis by the angiotensin analog when the molar ratio of [Sarl-Ile8]-angiotensin II: heptapeptide was 2:1. Since [Sarl-Ile8]-angiotensin II was a weak partial agonist at concentration greater than 5 X 10-7 M, the concentration of this peptide was held constant at 5 X 10-7 M and lower concentrations of heptapeptide were administered. Fifty percent inhibition was finally obtained when the molar ratio of [Sarl-Ile8]-angiotensin to heptapeptide was about 10: 1. The maximal inhibitory peptide ratio was about 50: 1.
DISCUSSION
The renin-angiotensin-aldosterone interaction is initiated by the release of renin. Some of the consequences of increased circulating renin are depicted diagrammatically in Fig. 2 . Since angiotensin II represents a potent vasoactive peptide elaborated subsequent to renin release, it is generally believed that angiotensin II is the peptide in this cascade that induces aldosterone biosynthesis. The des-Aspl-angiotensin II is reported to be a relatively inactive metabolite of angiotensin II, since it retains only 15% of the pressor activity of the octapeptide (11) . A recent structure-activity study by Blair-West (3) indicated that heptapeptide (des-Aspl-angiotensin II) markedly increased aldosterone secretion, while the hexapeptide (des-Aspl-arg2-Ang II) was completely inactive. On a molar basis, the heptapeptide was more potent than angiotensin II in stimulating aldosterone biosynthesis in vitro (4, 5) . The heptapeptide also appeared to exert a more immediate effect than angiotensin II as indicated by [ (3) (4) (5) , one may postulate a functional role comparable to that of converting enzyme for the angiotensinase As, namely the formation of heptapeptide. The extent that this enzymatic reaction is involved in the regulation of aldosterone by the renin-angiotensin system remains to be determined. In summary, [Sar'-Ile8]-angiotensin is a specific antagonist of angiotensin II in aldosterone biosynthesis. The molar ratio between antagonist to angiotensin II at 100% inhibition is about 2:1. However, the ratio between the antagonist and heptapeptide at 100% inhibition is about 50: 1.
